[Digital phenotyping of obesity, an innovative tool for a personalized therapeutic pathway]
- PMID: 40669975
- DOI: 10.1016/j.soin.2025.05.010
[Digital phenotyping of obesity, an innovative tool for a personalized therapeutic pathway]
Abstract
Obesity today represents a major public health challenge, closely associated with numerous chronic comorbidities and a graduated interdisciplinary therapeutic approach. Precise phenotyping of affected patients is essential to adapt management. The identification of distinct phenotypes opens up new perspectives for precision medicine and optimizes therapeutic strategies. How can digital phenotyping overcome some of the current obstacles in obesity care pathways?
Keywords: Nuvee; care pathways; digital; numérique; obesity; obésité; parcours de soins; phenotyping; phénotypage.
Copyright © 2025 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Déclaration de liens d’intérêts Cyril Gauthier : associé et directeur médical EPSD Nuvee, laboratoires Novo Nordisk (intervention congrès, participation board), laboratoires Lilly (congrès, participation board). Matthieu Poussier : laboratoires Novo Nordisk (congrès, participation board). Laura Oliveri : associée et présidente EPSD Nuvee.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical